pembrolizumab,eftilagimod alpha
merck,immutep
['congrat', 'eftilagimod', 'pembro']
yesterday, dr. adkins presented the phase iib study of eftilagimod alpha &amp; pembrolizumab as first-line treatment of patients w/ recurrent or metastatic head&amp;neck squamous cell carcinoma poster at . congrats to all #asco22 poster presenters! 
A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network